Caricamento...
Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not ach...
Salvato in:
| Pubblicato in: | Pharmaceutics |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7151083/ https://ncbi.nlm.nih.gov/pubmed/32178288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics12030256 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|